Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials

U. Platzbecker, P. Fenaux, L. Adès, A. Giagounidis, V. Santini, A. A. van de Loosdrecht, D. Bowen, T. de Witte, G. Garcia-Manero, E. Hellström-Lindberg, U. Germing, R. Stauder, L. Malcovati, Mikkael A. Sekeres, David P. Steensma, S. Gloaguen

Blood (2019) 133 (10): 1020–1030.

https://doi.org/10.1182/blood-2018-06-857102

Published: 2019

Journal Articles

Risk Factors for Disease Progression in del(5q) MDS Patients Treated with Lenalidomide.

Aristoteles A. Giagounidis, MD, Sabine Haase, Uwe Platzbecker, MD PhD, Ulrich Germing, MD PhD, Vera Lohrbacher, Gerhard Ehninger, MD PhD, Carlo Aul, MD PhD

Blood (2007) 110 (11): 1460.

https://doi.org/10.1182/blood.V110.11.1460.1460

Published: 2007

Journal Articles

Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study.

Pierre Fenaux, MD, G.J. Mufti, MD, V. Santini, MD, C. Finelli, MD, A. Giagounidis, MD, R. Schoch, MD, A.F. List, MD, S.D. Gore, MD, J.F. Seymour, MD, E. Hellstrom-Lindberg, MD, J.M. Bennett, MD, J.C. Byrd, MD, J.T. Backstrom, MD, L.S. Zimmerman, BSN, D.R. McKenzie, MS, C.L. Beach, PharmD, L.R. Silverman, MD

Blood (2007) 110 (11): 817.

https://doi.org/10.1182/blood.V110.11.817.817

Published: 2007

Journal Articles

Lenalidomide Is Likely To Improve Overall Survival in Patients with del(5q) Myelodysplastic Syndrome with a Complex Karyotype.

Aristoteles A. Giagounidis, MD, Sabine Haase, Ulrich Germing, MD PhD, Gundula Göhring-Michaelsen, Brigitte Schlegelberger, MD PhD, Carlo Aul, MD PhD

Blood (2006) 108 (11): 4860.

https://doi.org/10.1182/blood.V108.11.4860.4860

Published: 2006

Journal Articles

Correlation of Cytogenetic Findings with Morphology, Clinical Course and Prognosis in 2124 Patients with MDS.

D. Haase, C. Steidl, J. Schanz, R. Schabla, M. Pfeilstöcker, T. Nösslinger, B. Hildebrandt, A. Kuendgen, M. Lübbert, B. Kunzmann, A. Giagounidis, C. Aul, L. Trümper, O. Krieger, C. Fonatsch, P. Valent, R. Stauder, U. Germing

Blood (2005) 106 (11): 787.

https://doi.org/10.1182/blood.V106.11.787.787

Published: 2005

NARROW

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials

Risk Factors for Disease Progression in del(5q) MDS Patients Treated with Lenalidomide.

Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study.

Lenalidomide Is Likely To Improve Overall Survival in Patients with del(5q) Myelodysplastic Syndrome with a Complex Karyotype.

Correlation of Cytogenetic Findings with Morphology, Clinical Course and Prognosis in 2124 Patients with MDS.

Email alerts

ASH Publications

American Society of Hematology

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials

Risk Factors for Disease Progression in del(5q) MDS Patients Treated with Lenalidomide.

Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study.

Lenalidomide Is Likely To Improve Overall Survival in Patients with del(5q) Myelodysplastic Syndrome with a Complex Karyotype.

Correlation of Cytogenetic Findings with Morphology, Clinical Course and Prognosis in 2124 Patients with MDS.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only